Known targets — ChEMBL curated mechanism
ADORA1ADORA2AADORA2BADORA3PDE3APDE3BPDE4APDE4BPDE4CPDE4D
The experimentally established mechanism targets of Methionine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BHMT | Q93088 | 11/20 | 0.46 |
| ▸ | BHMT2 | Q9H2M3 | 1/20 | 0.45 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.43 |
| ▸ | GSR | P00390 | 2/20 | 0.42 |
| ▸ | GRM8 | O00222 | 1/20 | 0.42 |
| ▸ | GRM6 | O15303 | 1/20 | 0.42 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.42 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.42 |
| ▸ | GRM5 | P41594 | 1/20 | 0.42 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.42 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.42 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.42 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.42 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.42 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.42 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.42 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.42 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Racemethionine SCHEMBL23361938 | 0.93 | BHMT (0.52) | BHMTBHMT2RNPEPGSRGRM8 | |
| Racemethionine SCHEMBL23361943 | 0.93 | BHMT (0.52) | BHMTBHMT2RNPEPGSRGRM8 | |
| Racemethionine SCHEMBL23648682 | 0.93 | BHMT (0.52) | BHMTBHMT2RNPEPGSRGRM8 | |
| Racemethionine SCHEMBL23361957 | 0.93 | BHMT (0.52) | BHMTBHMT2RNPEPGSRGRM8 | |
| Racemethionine SCHEMBL23361966 | 0.93 | BHMT (0.52) | BHMTBHMT2RNPEPGSRGRM8 | |
| Racemethionine SCHEMBL23361948 | 0.93 | BHMT (0.52) | BHMTBHMT2RNPEPGSRGRM8 | |
| Racemethionine SCHEMBL23361956 | 0.93 | BHMT (0.52) | BHMTBHMT2RNPEPGSRGRM8 | |
| Racemethionine SCHEMBL23361955 | 0.93 | BHMT (0.52) | BHMTBHMT2RNPEPGSRGRM8 | |
| Racemethionine SCHEMBL23361947 | 0.93 | BHMT (0.52) | BHMTBHMT2RNPEPGSRGRM8 | |
| Racemethionine SCHEMBL23361953 | 0.93 | BHMT (0.52) | BHMTBHMT2RNPEPGSRGRM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210324027-A1 | MODIFIED INTERLEUKIN-7 PROTEINS AND USES THEREOF | GENEXINE, INC. (KR) | 2021-10-21 | — | — | US | claimed |
| US-7968310-B2 | Tagged sialyltransferase proteins | BIOGENERIX AG (DE) | 2011-06-28 | — | — | US | claimed |
| US-20210324027-A1 | MODIFIED INTERLEUKIN-7 PROTEINS AND USES THEREOF | GENEXINE, INC. (KR) | 2021-10-21 | — | — | US | disclosed |
| US-8372612-B2 | Production of four carbon alcohols using improved strain | BUTAMAX(TM) ADVANCED BIOFUELS LLC (US) | 2013-02-12 | — | — | US | disclosed |
| US-20090203139-A1 | PRODUCTION OF FOUR CARBON ALCOHOLS USING IMPROVED STRAIN | E.I. DU PONT DE NEMOURS AND COMPANY | 2009-08-13 | — | — | US | disclosed |
| WO-2009082681-A1 | PRODUCTION OF FOUR CARBON ALCOHOLS USING IMPROVED STRAIN | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2009-07-02 | — | — | WO | disclosed |
| US-20070032403-A1 | Crystal structure of the ITK kinase domain | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2007-02-08 | — | — | US | disclosed |
| WO-2005066335-A1 | CRYSTAL STRUCTURE OF THE INTERLEUKIN-2-INDUCIBLE CELL KINASE (ITK) KINASE DOMAIN | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-07-21 | — | — | WO | disclosed |
| US-20030097684-A1 | Lipid acyl hydrolases and variants thereof | MAXYGEN, INC. | 2003-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032403-A1 | Crystal structure of the ITK kinase domain | ITK, DTYMK, WEE1 | BHMT 2689/4885BHMT2 3303/4885RNPEP 1197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.